Loading...

Home
ETF
KNSA

KNSA

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press

Markets

Market Analysis
Crypto
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

AI Strategies

AI Stock Picker
Swing Trading
SwingMax Portfolio
Quant AI Alpha Pick
CoinSwing
Daytrading Center
Crypto Radar
Patterns Detection

Resources

Blog
Tutorial
Help Center
Affiliate Program

Products

Chat With Tia
AI Screener
Backtest Playground
Featured Screeners
AI Earnings Calendar
Thematic Investing
Whales Auto Tracker

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

Explore AI Stock Picker
Master Swing Trading
Follow SwingMax Portfolio
Discover QuantAI Alpha Pick
Follow Whales Auto Tracker
Navigate Daytrading Center
Learn Patterns Detection
Meet Financial AI Agent
Maximize AI Screener
Why Backtesting Playground
Forecast AI Earnings Prediction
Setup Stock Monitor
Deep Dive into Tech Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

KNSA News

Kiniksa Reports $677.5M in 2025 ARCALYST Revenue, 62% Growth

Jan 12 2026Globenewswire

Kinaset Therapeutics Closes $103 Million Series B Financing to Advance Inhaled Asthma Treatment

Jan 11 2026Businesswire

From Olema to Insmed: Do These Soaring Biotechs Still Present a Good Investment Opportunity?

Nov 19 2025NASDAQ.COM

Kiniksa Pharmaceuticals Executive Offloads Shares Valued at $1,962,781, Recent SEC Filing Reveals

Oct 22 2025Yahoo Finance

Analysis Indicates VBK Could Reach $342

Oct 22 2025NASDAQ.COM

Wells Fargo Keeps Overweight Rating on Kiniksa Pharmaceuticals and Increases Price Target to $45

Sep 25 2025Benzinga

Zacks Industry Outlook Spotlights Halozyme Therapeutics, Akero Therapeutics, Kiniska Pharmaceuticals, ANI Pharmaceuticals, and Twist BioScience

Sep 24 2025NASDAQ.COM

Kiniksa Pharmaceuticals International, plc (KNSA) Shows Promising Momentum: Reasons for Potential Sustainability

Sep 19 2025NASDAQ.COM

7 Biotech Stocks Reaching 52-Week Highs - Will the Uptrend Persist?

Sep 15 2025NASDAQ.COM

Cytokinetics Rises Following Encouraging Late-Stage Study Results for Cardiomyopathy

Sep 03 2025NASDAQ.COM

Understanding the Recent Price Movement of Kiniksa Pharmaceuticals International, plc (KNSA) and Its Benefits

Sep 03 2025NASDAQ.COM

Court Decision and Tariff Ambiguity: Is It Time to Invest in POST, TME, and KNSA?

Sep 02 2025NASDAQ.COM

ALNY/RHHBY's Zilebesiran Advances to Phase III Following Third Phase II Success

Sep 01 2025NASDAQ.COM

Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y

Aug 13 2025NASDAQ.COM

Why CommScope Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket

Aug 04 2025Benzinga

Jefferies Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $54

Jul 29 2025Benzinga